Advertisement

Breast Cancer Prevention

  • Patricia A. Thompson
  • Ana Maria Lopez
  • Alison Stopeck

Keywords

Breast Cancer Breast Cancer Risk Mammographic Density Breast Cancer Prevention Gail Model 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. (1996). "Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies. Collaborative Group on Hormonal Factors in Breast Cancer." Lancet 347(9017): 1713–1727.Google Scholar
  2. (2002). "Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial." Lancet 359(9324): 2131–2139.Google Scholar
  3. (2002). "Using Medication To Prevent Breast Cancer: Recommendations from the United States Preventive Services Task Force." Ann Intern Med 137(1): 162.Google Scholar
  4. ACS (2004). Breast Cancer Facts and Figures 2003–2004, American Cancer Society: http://www.cancer.org/downloads/STT/CAFF2003BrFPWSecured.pdf, accessed 11/20/04.Google Scholar
  5. Albert, K.S. and CM. Gernaat (1984). "Pharmacokinetics of ibuprofen." Am J Med 77(1 A): 40–46.PubMedGoogle Scholar
  6. Amir, E., D.G. Evans, et al. (2003). "Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme." J Med Genet 40(11): 807–814.CrossRefPubMedGoogle Scholar
  7. Anderson, G.L., M. Limacher, et al. (2004). "Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative randomized controlled trial." JAMA 291(14): 1701–1712.CrossRefPubMedGoogle Scholar
  8. Antoine, C, F. Liebens, et al. (2004). "Influence of HRT on prognostic factors for breast cancer: a systematic review after the Women's Health Initiative trial." Hum Reprod 19(3): 741–756.CrossRefPubMedGoogle Scholar
  9. Antoniou, A., P. D. Pharoah, et al. (2003). "Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies." Am J Hum Genet 72(5): 1117–1130.CrossRefPubMedGoogle Scholar
  10. Bolan, P.J., S. Meisamy, et al. (2003). "In vivo quantification of choline compounds in the breast with 1H MR spectroscopy." Magn Reson Med 50(6): 1134–1143.CrossRefPubMedGoogle Scholar
  11. Boland, G.P., W.F. Knox, et al. (2002). "Molecular markers and therapeutic targets in ductal carcinoma in situ." Microsc Res Tech 59(1): 3–11.CrossRefPubMedGoogle Scholar
  12. Boyd, N.F., G.A. Lockwood, et al. (1998). "Mammographic densities and breast cancer risk." Cancer Epidemiol Biomarkers Prev 7(12): 1133–1144.PubMedGoogle Scholar
  13. Boyd, N.F., L.J. Martin, et al. (2001). "Mammographic densities as a marker of human breast cancer risk and their use in chemoprevention." Curr Oncol Rep 3(4): 314–321.PubMedGoogle Scholar
  14. Buist, D.S.M., P.L. Porter, et al. (2004). "Factors Contributing to Mammography Failure in Women Aged 40–49 Years." J Natl Cancer Inst 96(19): 1432–1440.PubMedGoogle Scholar
  15. Byers, T., M. Nestle, et al. (2002). "American Cancer Society Guidelines on Nutrition and Physical Activity for Cancer Prevention: Reducing the Risk of Cancer with Healthy Food Choices and Physical Activity." CA Cancer J Clin 52(2): 92–119.PubMedGoogle Scholar
  16. Calderon-Margalit, R. and O. Paltiel (2004). "Prevention of breast cancer in women who carry BRCA1 or BRCA2 mutations: a critical review of the literature." IntJCancer 112(3): 357–364.Google Scholar
  17. Calle, E. E., H. Frumkin, et al. (2002). "Organochlorines and Breast Cancer Risk." CA Cancer J Clin 52(5): 301–309.PubMedGoogle Scholar
  18. Carmichael, A., A.S. Sami, et al. (2003). "Breast cancer risk among the survivors of atomic bomb and patients exposed to therapeutic ionising radiation." European Journal of Surgical Oncology 29(5): 475–479.CrossRefPubMedGoogle Scholar
  19. Cauley, J.A., L. Norton, et al. (2001). "Continued breast cancer risk reduction in postmeno-pausal women treated with raloxifene: 4-year results from the MORE trial. Multiple out-comes of raloxifene evaluation." Breast Cancer Res Treat 65(2): 125–134.CrossRefPubMedGoogle Scholar
  20. Cerhan, J.R., J.D. Potter, et al. (2004). "Adherence to the AICR Cancer Prevention Recommendations and Subsequent Morbidity and Mortality in the Iowa Women's Health Study Cohort." Cancer Epidemiol Biomarkers Prev 13(7): 1114–1120.PubMedGoogle Scholar
  21. Chlebowski, R.T., M. Pettinger, et al. (2004). "Insulin, Physical Activity, and Caloric Intake in Postmenopausal Women: Breast Cancer Implications." J Clin Oncol 22(22): 4507–4513.CrossRefPubMedGoogle Scholar
  22. Claus, E.B., N. Risch, et al. (1991). "Genetic analysis of breast cancer in the cancer and steroid hormone study." Am J Hum Genet 48(2): 232–242.PubMedGoogle Scholar
  23. Claus, E. B., M. Stowe, et al. (2003). "The risk of a contralateral breast cancer among women diagnosed with ductal and lobular breast carcinoma in situ: data from the Connecticut Tumor Registry." The Breast 12(6): 451–456.CrossRefPubMedGoogle Scholar
  24. Clemons, M., L. Loijens, et al. (2000). "Breast cancer risk following irradiation for Hodgkin's disease." Cancer Treatment Reviews 26(4): 291–302.CrossRefPubMedGoogle Scholar
  25. Colditz, G.A. and B. Rosner (2000). "Cumulative risk of breast cancer to age 70 years according to risk factor status: data from the Nurses' Health Study." Am J Epidemiol 152(10): 950–964.CrossRefPubMedGoogle Scholar
  26. Costa, A., F. Formelli, et al. (1994). "Prospects of chemoprevention of human cancers with the synthetic retinoid fenretinide." Cancer Res 54(7 Suppl): 2032s–2037s.PubMedGoogle Scholar
  27. Coyle, Y. M. (2004). "The effect of environment on breast cancer risk." Breast Cancer Res Treat 84(3): 273–288.CrossRefPubMedGoogle Scholar
  28. Davies, G.L. (2003). "Cyclooxygenase-2 and chemoprevention of breast cancer." J Steroid Biochem Mol Biol 86(3–5): 495–499.CrossRefPubMedGoogle Scholar
  29. Decensi, A., D. Serrano, et al. (2003). "Breast cancer prevention trials using retinoids." J Mammary Gland Biol Neoplasia 8(1): 19–30.CrossRefPubMedGoogle Scholar
  30. Deligeoroglou, E., E. Michailidis, et al. (2003). "Oral Contraceptives and Reproductive System Cancer." Ann NY Acad Sci 997(1): 199–208.CrossRefPubMedGoogle Scholar
  31. Dupont, W. D. and D.L. Page (1985). "Risk factors for breast cancer in women with proliferative breast disease." N Engl J Med 312(3): 146–151.PubMedGoogle Scholar
  32. Dupont, W.D., D.L. Page, et al. (1994). "Long-Term Risk of Breast Cancer in Women with Fibroadenoma." N Engl J Med 331(1): 10–15.CrossRefPubMedGoogle Scholar
  33. Erbas, B., A. Amos, et al. (2004). "Incidence of Invasive Breast Cancer and Ductal Carcinoma In situ in a Screening Program by Age: Should Older Women Continue Screening?" Cancer Epidemiol Biomarkers Prev 13(10): 1569–1573.PubMedGoogle Scholar
  34. Ernster, V. L., J. Barclay, et al. (1996). "Incidence of and treatment for ductal carcinoma in situ of the breast." JAMA 275(12): 913–918.CrossRefPubMedGoogle Scholar
  35. Fisher, B., J.P. Costantino, et al. (1998). "Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study." J Natl Cancer Inst 90(18): 1371–1388.CrossRefPubMedGoogle Scholar
  36. Fournier, A., F. Berrino, et al. (2004). "Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort." Int J Cancer 114(3):448–454.CrossRefGoogle Scholar
  37. Gail, M.H., L.A. Brinton, et al. (1989). "Projecting individualized probabilities of developing breast cancer for white females who are being examined annually." J Natl Cancer Inst 81(24): 1879–1886.PubMedGoogle Scholar
  38. Gail, M.H., J.P. Costantino, et al. (1999). "Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer." J Natl Cancer Inst 91(21): 1829–1846.CrossRefPubMedGoogle Scholar
  39. Gammon, M. D., S.M. Eng, et al. (2004). "Environmental tobacco smoke and breast cancer incidence." Environmental Research 96(2): 176–185.CrossRefPubMedGoogle Scholar
  40. Garbe, E., L. Levesque, et al. (2004). "Variability of breast cancer risk in observational studies of hormone replacement therapy: a meta-regression analysis." Maturitas 47(3): 175–183.CrossRefPubMedGoogle Scholar
  41. Garfinkel, L, C. C. Boring, et al. (1994). "Changing trends. An overview of breast cancer incidence and mortality." Cancer 74(1 Suppl): 222–227.PubMedGoogle Scholar
  42. Ghafoor, A., A. Jemal, et al. (2003). "Trends in Breast Cancer by Race and Ethnicity." CA Cancer J Clin 53(6): 342–355.PubMedGoogle Scholar
  43. Giordano, S.H., A.U. Buzdar, et al. (2002). "Breast Cancer in Men." Ann Intern Med 137(8): 678–687.PubMedGoogle Scholar
  44. Goss, P. E. and K. Strasser-Weippl (2004). "Prevention Strategies with Aromatase Inhibitors." Clin Cancer Res 10(1): 372–379.CrossRefGoogle Scholar
  45. Haffty, B.G., C. Lee, et al. (1998). "Prognostic significance of mammographic detection in a cohort of conservatively treated breast cancer patients." Cancer J Sci Am 4(1): 35–40.PubMedGoogle Scholar
  46. Hankinson, S. E., W.C. Willett, et al. (1998). "Circulating concentrations of insulin-like growth factor I and risk of breast cancer." Lancet 351(9113): 1393–1396.CrossRefPubMedGoogle Scholar
  47. Harris, R.E., R.T. Chlebowski, et al. (2003). "Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women's Health Initiative." Cancer Res 63(18): 6096–6101.PubMedGoogle Scholar
  48. Hartmann, L.C., D.J. Schaid, et al. (1999). "Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer." N Engl J Med 340(2): 77–84.CrossRefPubMedGoogle Scholar
  49. Hemminki, K., R. Rawal, et al. (2004). "Mammographic Screening Is Dramatically Changing Age-Incidence Data for Breast Cancer." J Clin Oncol 22(22): 4652–4653.CrossRefPubMedGoogle Scholar
  50. Henderson, B.E. and L. Bernstein (1991). "The international variation in breast cancer rates: an epidemiological assessment." Breast Cancer Res Treat 18(Suppl 1): S11–17.CrossRefPubMedGoogle Scholar
  51. Hodgson, S.V., P.J. Morrison, et al. (2004). "Breast cancer genetics: unsolved questions and open perspectives in an expanding clinical practice." Am J Med Genet 129C(1): 56–64.CrossRefGoogle Scholar
  52. Hollingsworth, A.B., S.E. Singletary, et al. (2004). "Current comprehensive assessment and management of women at increased risk for breast cancer." The American Journal of Surgery 187(3): 349–362.CrossRefGoogle Scholar
  53. Holmes, M.D. and W.C. Willett (2004). "Does diet affect breast cancer risk?" Breast Cancer Res 6(4): 170–178.CrossRefPubMedGoogle Scholar
  54. Humphrey, L.L., M. Helfand, et al. (2002). "Breast cancer screening: a summary of the evidence for the U.S. Preventive Services Task Force." Ann Intern Med 137(5 Part 1): 347–360.PubMedGoogle Scholar
  55. Jemal, A., R.C. Tiwari, et al. (2004). "Cancer statistics, 2004." CA Cancer J Clin 54(1): 8–29.PubMedGoogle Scholar
  56. Jernstrom, H., C. Lerman, et al. (1999). "Pregnancy and risk of early breast cancer in carriers of BRCA1 and BRCA2." The Lancet 354(9193): 1846–1850.CrossRefGoogle Scholar
  57. Johnson, T.W., K. E. Anderson, et al. (2002). "Association of aspirin and nonsteroidal anti-inflammatory drug use with breast cancer." Cancer Epidemiol Biomarkers Prev 11(12): 1586–1591.PubMedGoogle Scholar
  58. Kaaks, R. (1996). "Nutrition, hormones, and breast cancer: is insulin the missing link?" Cancer Causes Control 7(6): 605–625.CrossRefPubMedGoogle Scholar
  59. Kelsey, J.L. and L. Bernstein (1996). "Epidemiology and prevention of breast cancer." Annu Rev Public Health 17: 47–67.CrossRefPubMedGoogle Scholar
  60. Key, T.J., A. Schatzkin, et al. (2004). "Diet, nutrition and the prevention of cancer." Public Health Nutr 7(1 A): 187–200.CrossRefPubMedGoogle Scholar
  61. Kollias, J., I.O. Ellis, et al. (1999). "Clinical and histological predictors of contralateral breast cancer." Eur J Surg Oncol 25(6): 584–589.CrossRefPubMedGoogle Scholar
  62. Lacroix, M., R.A. Toillon, et al. (2004). "Stable ‘portrait’ of breast tumors during progression: data from biology, pathology and genetics." Endocr Relat Cancer 11(3): 497–522.CrossRefPubMedGoogle Scholar
  63. Laden, F. and D.J. Hunter (1998). "Environmental risk factors and female breast cancer." Annu Rev Public Health 19: 101–123.CrossRefPubMedGoogle Scholar
  64. Law, M. (2000). "Dietary fat and adult diseases and the implications for childhood nutrition: an epidemiologic approach." Am J Clin Nutr 72(5): 1291–1296.Google Scholar
  65. Li, C.I., B.O. Anderson, et al. (2002). "Changing incidence of lobular carcinoma in situ of the breast." Breast Cancer Res Treat 75(3): 259–268.CrossRefPubMedGoogle Scholar
  66. Lo, S.S. and V.G. Vogel (2004). "Endocrine prevention of breast cancer using selective oestrogen receptor modulators (SORMs)." Best Practice & Research Clinical Endocrinology & Metabolism 18(1): 97–111.Google Scholar
  67. Louie, A.Y., M.M. Huber, et al. (2000). "In vivo visualization of gene expression using magnetic resonance imaging." Not Biotechnol 18(3): 321–325.CrossRefGoogle Scholar
  68. Moorman, P.G., J.M. Grubber, et al. (2003). "Association between non-steroidal anti-inflammatory drugs (NSAIDs) and invasive breast cancer and carcinoma in situ of the breast." Cancer Causes Control 14(10): 915–922.CrossRefPubMedGoogle Scholar
  69. Morris, E.A., L. Liberman, et al. (2003). "MRI of occult breast carcinoma in a high-risk population." Am J Roentgenol 181(3): 619–626.Google Scholar
  70. Narod, S.A. and W.D. Foulkes (2004). "BRCA1 and BRCA2: 1994 and beyond." Nature Reviews Cancer 4(9): 665–676.CrossRefPubMedGoogle Scholar
  71. Nayfield, S.G., J.E. Karp, et al. (1991). "Potential role of tamoxifen in prevention of breast cancer." J Natl Cancer Inst 83(20): 1450–1459.PubMedGoogle Scholar
  72. Nelson, H.D., L.L. Humphrey, et al. (2002). "Postmenopausal hormone replacement therapy: scientific review." JAMA 288(7): 872–881.CrossRefPubMedGoogle Scholar
  73. Olsen, J.H., N. Seersholm, et al. (1999). "Cancer risk in close relatives of women with early-onset breast cancer — a population-based incidence study." Br J Cancer 79(3–4): 673–679.CrossRefPubMedGoogle Scholar
  74. Page, D.L. (2004). "Breast lesions, pathology and cancer risk." Breast J 10(Suppl 1): S3–4.CrossRefGoogle Scholar
  75. Page, D.L. and R.A. Jensen (1994). "Evaluation and management of high risk and premalignant lesions of the breast." World J Surg 18(1): 32–38.CrossRefPubMedGoogle Scholar
  76. Parker, E. D. and A.R. Folsom (2003). "Intentional weight loss and incidence of obesity-related cancers: the Iowa Women's Health Study." Int J Obes Relat Metab Disord 27(12): 1447–1452.CrossRefPubMedGoogle Scholar
  77. Parkin, D.M. (2004). "International variation." Oncogene 23(38): 6329–6340.CrossRefPubMedGoogle Scholar
  78. Pike, M.C., C.L. Pearce, et al. (2004). "Prevention of cancers of the breast, endometrium and ovary." Oncogene 23(38): 6379–6391.CrossRefPubMedGoogle Scholar
  79. Powles, T., R. Eeles, et al. (1998). "Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial." Lancet 352(9122): 98–101.PubMedGoogle Scholar
  80. Radimer, K. L., R. Ballard-Barbash, et al. (2004). "Weight change and the risk of late-onset breast cancer in the original Framingham cohort." Nutr Cancer 49(1): 7–13.CrossRefPubMedGoogle Scholar
  81. Rebbeck, T.R., A.M. Levin, et al. (1999). "Breast cancer risk after bilateral prophylactic oo-phorectomy in BRCA1 mutation carriers." J Natl Cancer Inst 91(17): 1475–1479.CrossRefPubMedGoogle Scholar
  82. Ries, L.A.G., M.P. Eisner, et al. (2004). SEER Cancer Statistics Review, 1995 2001. Bethesda, MD, National Cancer Institute.Google Scholar
  83. Rockhill, B., D. Spiegelman, et al. (2001). "Validation of the Gail et al. Model of Breast Cancer Risk Prediction and Implications for Chemoprevention." J Natl Cancer Inst 93(5): 358–366.CrossRefPubMedGoogle Scholar
  84. Rossouw, J. E., G. L. Anderson, et al. (2002). "Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial." JAMA 288(3): 321–333.CrossRefPubMedGoogle Scholar
  85. Ruffin, M.T.T., D.A. August, et al. (1993). "Selection criteria for breast cancer chemoprevention subjects." J Cell Biochem Suppl 17G: 234–241.CrossRefPubMedGoogle Scholar
  86. Sakorafas, G.H., E. Krespis, et al. (2002). "Risk estimation for breast cancer development; a clinical perspective." Surg Oncol 10(4): 183–192.CrossRefPubMedGoogle Scholar
  87. Serrano, D., E. Perego, et al. (2004). "Progress in chemoprevention of breast cancer." Critical Reviews in Oncology/Hematology 49(2): 109–117.CrossRefPubMedGoogle Scholar
  88. Shen, Q. and P.H. Brown (2003). "Novel agents for the prevention of breast cancer: targeting transcription factors and signal transduction pathways." J Mammary Gland Biol Neoplasia 8(1): 45–73.CrossRefPubMedGoogle Scholar
  89. Shi, R., H. Yu, et al. (2004). "IGF-I and breast cancer: a meta-analysis." Int J Cancer 111(3): 418–423.CrossRefPubMedGoogle Scholar
  90. Smith, R.A. (2000). "Breast cancer screening among women younger than age 50: a current assessment of the issues." CA Cancer J Clin 50(5): 312–336.PubMedGoogle Scholar
  91. Smith, R.A., D. Saslow, et al. (2003). "American Cancer Society guidelines for breast cancer screening: update 2003." CA Cancer J Clin 53(3): 141–169.PubMedGoogle Scholar
  92. Stankovic, T, A.M. Kidd, et al. (1998). "ATM mutations and phenotypes in ataxia-telangiectasia families in the British Isles: expression of mutant ATM and the risk of leukemia, lymphoma, and breast cancer." Am J Hum Genet 62(2): 334–345.CrossRefPubMedGoogle Scholar
  93. Stoll, B.A. (1998). "Western diet, early puberty, and breast cancer risk." Breast Cancer Res Treat 49(3): 187–193.CrossRefPubMedGoogle Scholar
  94. Stoll, B.A. (1999). "Western nutrition and the insulin resistance syndrome: a link to breast cancer." Eur J Clin Nutr 53(2): 83–87.CrossRefPubMedGoogle Scholar
  95. Sugumar, A., Y.C. Liu, et al. (2004). "Insulin-like growth factor (IGF)-I and IGF-binding protein 3 and the risk of premenopausal breast cancer: a meta-analysis of literature." Int J Cancer 111(2): 293–297.CrossRefPubMedGoogle Scholar
  96. Terry, M.B., M. D. Gammon, et al. (2004). "Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk." JAMA 291(20): 2433–2440.CrossRefPubMedGoogle Scholar
  97. The Women's Health Initiative Steering Committee (2004). "Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative randomized controlled trial." JAMA 291(14): 1701–1712.Google Scholar
  98. Thomas, D.B., D.L. Gao, et al. (1997). "Randomized trial of breast self-examination in Shanghai: methodology and preliminary results." J Natl Cancer Inst 89(5): 355–365.CrossRefPubMedGoogle Scholar
  99. Tobias, J.S. (2004). "Recent advances in endocrine therapy for postmenopausal women with early breast cancer: implications for treatment and prevention." Ann Oncol 15(12): 1738–1747.CrossRefPubMedGoogle Scholar
  100. Toniolo, P., P. F. Bruning, et al. (2000). "Serum insulin-like growth factor-l and breast cancer." Int J Cancer 88(5): 828–832.CrossRefPubMedGoogle Scholar
  101. Tryggvadottir, L, E.J. Olafsdottir, et al. (2003). "BRCA2 mutation carriers, reproductive factors and breast cancer risk." Breast Cancer Res 5(5): R121–128.CrossRefPubMedGoogle Scholar
  102. Tyrer, J., S.W. Duffy, et al. (2004). "A breast cancer prediction model incorporating familial and personal risk factors." Stat Med 23(7): 1111–1130.CrossRefPubMedGoogle Scholar
  103. Vogel, V.G. (1991). "High-risk populations as targets for breast cancer prevention trials." Preventive Medicine 20(1): 86–100.CrossRefPubMedGoogle Scholar
  104. Vogel, V.G. (2004). "Atypia in the assessment of breast cancer risk: implications for management." Diagn Cytopathol 30(3): 151–157.CrossRefPubMedGoogle Scholar
  105. Ward, E., A. Jemal, et al. (2004). "Cancer disparities by race/ethnicity and socioeconomic status." CA Cancer J Clin 54(2): 78–93.PubMedGoogle Scholar
  106. Warren Burhenne, L.J., S.A. Wood, et al. (2000). "Potential contribution of computer-aided detection to the sensitivity of screening mammography." Radiology 215(2): 554–562.PubMedGoogle Scholar
  107. Warren, R. (2004). "Hormones and mammographic breast density." Maturitas 49(1): 67–78.CrossRefPubMedGoogle Scholar
  108. Weissleder, R., A. Moore, et al. (2000). "In vivo magnetic resonance imaging of transgene expression." Nat Med 6(3): 351–355.CrossRefPubMedGoogle Scholar
  109. White, S., R. Taetle, et al. (1990). "Combinations of anti-transferrin receptor monoclonal antibodies inhibit human tumor cell growth in vitro and in vivo: evidence for synergistic antiproliferative effects." Cancer Res 50(19): 6295–6301.PubMedGoogle Scholar
  110. Wu, K., H.-T. Kim, et al. (2002). "Suppression of Mammary Tumorigenesis in Transgenic Mice by the RXR-selective Retinoid, LGD1069." Cancer Epidemiol Biomarkers Prev 11(5): 467–474.PubMedGoogle Scholar
  111. Yang, L.M., U.C. Tin, et al. (1999). "Role of retinoid receptors in the prevention and treatment of breast cancer." J Mammary Gland Biol Neoplasia 4(4): 377–388CrossRefPubMedGoogle Scholar

Copyright information

© Springer Berlin Heidelberg 2005

Authors and Affiliations

  • Patricia A. Thompson
    • 1
  • Ana Maria Lopez
    • 1
  • Alison Stopeck
    • 1
  1. 1.College of MedicineUniversity of ArizonaTucson

Personalised recommendations